Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone
2024 ASCO Annual Meeting
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Charter two was found positive for the primary outcome. At the time of the report of the results, there was a statistically significant difference of five months in terms of progression-free survival in favor of the patients who received cabazitaxel plus abirateron. For patients who received cabazitaxel and abirateron, the median progression-free survival was 14.9 months versus 9.9 months for the patients who received abirateron alone. So technically, the addition of cabazitaxel prolonged the progression-free survival by a little bit more than 50%.
Even though charter two was found positive for the primary outcome, it is not a practice changing study. The main reason is because the landscape, the treatment landscape for metastatic castration-sensitive disease has changed, and there are not that many patients who are currently getting docetaxel plus androgen deprivation in the castration-sensitive setting.
Nowadays, most patients receive either a double treatment, which includes treatment with abirateron or enzalutamide or any of the other second generation androgen receptor inhibitors. In cases that the patients receive treatment with docetaxel, that is usually in the context of a triplet therapy, which means that in addition to the docetaxel, they also receive treatment with abirateron or darolutamide or enzalutamide. That is the main reason that by the time these patients develop castration-resistant disease, they have already been exposed to a second generation androgen receptor inhibitor, which of course is like abirateron.
As part of charter two, we did include two correlative studies that are in progress. The first one is the analysis of circulating tumor cells for splice variant seven, and the second one that we included in charter two was disease assessment using sodium fluoride PET imaging. This is ongoing work and hopefully we will be able to present those results in the future meeting. Also, as part of the study, we did collect plasma for patients who enrolled in the study, and we hope that we will be able to secure funding for some additional studies with those samples.
The ASCO Post Staff
Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).
The ASCO Post Staff
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).
The ASCO Post Staff
Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).
The ASCO Post Staff
Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).
The ASCO Post Staff
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).